Inclusion Criteria:

          -  18 Years to 70 Years, Male and female

          -  Survival time>12 weeks

          -  B cell lymphomas diagnosed by Physical examination,pathological examination,Laboratory
             tests and imaging tests

          -  Chemotherapy failure or recurrent B cell lymphomas

          -  Creatinine< 2.5mg/dl

          -  Glutamic-pyruvic transaminase, glutamic oxalacetic transaminase< 3 fold of normal
             level

          -  Bilirubin<2.0mg/dl

          -  Karnofsky Performance Status>50% at the time of screening

          -  Adequate pulmonary, renal, hepatic, and cardiac function

          -  Fail in autologous or allogenic haemopoietic stem cell transplantation

          -  Free of leukocytes removal contraindications

          -  Voluntarily join CAR-T clinical trial

          -  Understand and sign written informed consent

        Exclusion Criteria:

          -  Pregnant or nursing women or women with pregnancy plan in half a year

          -  Any infectious disease (HIV, active tuberculosis, ect.)

          -  Active hepatitis B, active hepatitis C infection

          -  Feasibility assessment proves that the efficiency of transduction of lymphocyte is
             below 10% or the lymphocyte amplification is below 5 fold with the costimulation of
             cluster of differentiation 3(CD 3)and cluster of differentiation 8(CD 8)

          -  Abnormal vital signs or cannot cooperate with the inspectors

          -  mental or psychological disease cannot cooperate with treatment and curative effect
             evaluation

          -  Highly allergic constitution or history of severe allergies, especially allergy to
             interleukin-2(IL-2)

          -  General infection or local severe infection, or other infection that is not controlled

          -  Dysfunction in lung, heart, kidney and brain

          -  Severe autoimmune diseases

          -  Other symptoms that are not applicable for CAR-T